Register entry
SUCAMPO PHARMA LIMITED LIABILITY COMPANY
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 2 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 2.
| Dosage form | NDCs |
|---|---|
| solution, concentrate | 2 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| sucampo pharma limited liability company | 2 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Lubiprostone Premix | solution, concentrate | 13299-0102DRUG FOR FURTHER PROCESSING |
| - | Lubiprostone Premix | solution, concentrate | 13299-0104DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is SUCAMPO PHARMA LIMITED LIABILITY COMPANY FDA approved?
- SUCAMPO PHARMA LIMITED LIABILITY COMPANY holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does SUCAMPO PHARMA LIMITED LIABILITY COMPANY make?
- 2 products are listed under SUCAMPO PHARMA LIMITED LIABILITY COMPANY in the openFDA NDC Directory, most often as solution, concentrate. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.